dPCR Technologies Enable Treatment and Response Monitoring in Patients Affected by Solid Tumors

Advancements in molecular analysis technologies enhance understanding of tumor biology, optimizing cancer patient management. Cell-free DNA (cfDNA), found in plasma and body fluids, offers tumor-derived genetic material, an alternative to tissue samples.

The detection of mutations in cfDNA from plasma has been demonstrated to be feasible and easily repeatable. Its implementation in clinical practice allows a better management of patients to select the appropriate treatment, and to monitor tumor dynamics during therapies. The introduction of highly sensitive techniques, including different digital PCR platforms, opened new scenarios in terms of comprehension of tumor heterogeneity and therapeutic strategies.